Cargando…

Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma

RNA binding proteins (RBPs) are increasingly appreciated as being essential for normal hematopoiesis and have a critical role in the progression of hematological malignancies. However, their functional consequences and clinical significance in diffuse large B‐cell lymphoma (DLBCL) remain unknown. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yongzhi, Luo, Ximei, He, Haiqing, Pan, Tao, He, Yizi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026940/
https://www.ncbi.nlm.nih.gov/pubmed/33749163
http://dx.doi.org/10.1002/cam4.3859
_version_ 1783675730140332032
author Xie, Yongzhi
Luo, Ximei
He, Haiqing
Pan, Tao
He, Yizi
author_facet Xie, Yongzhi
Luo, Ximei
He, Haiqing
Pan, Tao
He, Yizi
author_sort Xie, Yongzhi
collection PubMed
description RNA binding proteins (RBPs) are increasingly appreciated as being essential for normal hematopoiesis and have a critical role in the progression of hematological malignancies. However, their functional consequences and clinical significance in diffuse large B‐cell lymphoma (DLBCL) remain unknown. Here, we conducted a systematic analysis to identify RBP‐related genes affecting DLBCL prognosis based on the Gene Expression Omnibus database. By univariate and multivariate Cox proportional hazards regression (CPHR) methods, six RBPs‐related genes (CMSS1, MAEL, THOC5, PSIP1, SNIP1, and ZCCHC7) were identified closely related to the overall survival (OS) of DLBCL patients. The RBPs signature could efficiently distinguished low‐risk from high‐risk patients and could serve as an independent and reliable factor for predicting OS. Moreover, Gene Set Enrichment Analysis revealed 17 significantly enriched pathways between high‐ versus low‐risk group, including the regulation of autophagy, chronic myeloid leukemia, NOTCH signaling pathway, and B cell receptor signaling pathway. Then we developed an RBP‐based nomogram combining other clinical risk factors. The receiver operating characteristic curve analysis demonstrated high prognostic predictive efficiency of this model with the area under the curve values were 0.820 and 0.780, respectively, in the primary set and entire set. In summary, our RBP‐based model could be a novel prognostic predictor and had the potential for developing treatment targets for DLBCL.
format Online
Article
Text
id pubmed-8026940
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80269402021-04-13 Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma Xie, Yongzhi Luo, Ximei He, Haiqing Pan, Tao He, Yizi Cancer Med Clinical Cancer Research RNA binding proteins (RBPs) are increasingly appreciated as being essential for normal hematopoiesis and have a critical role in the progression of hematological malignancies. However, their functional consequences and clinical significance in diffuse large B‐cell lymphoma (DLBCL) remain unknown. Here, we conducted a systematic analysis to identify RBP‐related genes affecting DLBCL prognosis based on the Gene Expression Omnibus database. By univariate and multivariate Cox proportional hazards regression (CPHR) methods, six RBPs‐related genes (CMSS1, MAEL, THOC5, PSIP1, SNIP1, and ZCCHC7) were identified closely related to the overall survival (OS) of DLBCL patients. The RBPs signature could efficiently distinguished low‐risk from high‐risk patients and could serve as an independent and reliable factor for predicting OS. Moreover, Gene Set Enrichment Analysis revealed 17 significantly enriched pathways between high‐ versus low‐risk group, including the regulation of autophagy, chronic myeloid leukemia, NOTCH signaling pathway, and B cell receptor signaling pathway. Then we developed an RBP‐based nomogram combining other clinical risk factors. The receiver operating characteristic curve analysis demonstrated high prognostic predictive efficiency of this model with the area under the curve values were 0.820 and 0.780, respectively, in the primary set and entire set. In summary, our RBP‐based model could be a novel prognostic predictor and had the potential for developing treatment targets for DLBCL. John Wiley and Sons Inc. 2021-03-21 /pmc/articles/PMC8026940/ /pubmed/33749163 http://dx.doi.org/10.1002/cam4.3859 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Xie, Yongzhi
Luo, Ximei
He, Haiqing
Pan, Tao
He, Yizi
Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
title Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
title_full Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
title_fullStr Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
title_full_unstemmed Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
title_short Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
title_sort identification of an individualized rna binding protein‐based prognostic signature for diffuse large b‐cell lymphoma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026940/
https://www.ncbi.nlm.nih.gov/pubmed/33749163
http://dx.doi.org/10.1002/cam4.3859
work_keys_str_mv AT xieyongzhi identificationofanindividualizedrnabindingproteinbasedprognosticsignaturefordiffuselargebcelllymphoma
AT luoximei identificationofanindividualizedrnabindingproteinbasedprognosticsignaturefordiffuselargebcelllymphoma
AT hehaiqing identificationofanindividualizedrnabindingproteinbasedprognosticsignaturefordiffuselargebcelllymphoma
AT pantao identificationofanindividualizedrnabindingproteinbasedprognosticsignaturefordiffuselargebcelllymphoma
AT heyizi identificationofanindividualizedrnabindingproteinbasedprognosticsignaturefordiffuselargebcelllymphoma